IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes - ScienceDirect
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUAL V - Media Centre | EASD
Novo Nordisk debuts diabetes combo in Mexico - PMLiVE
Novo Nordisk and Sanofi diabetes combo drugs receive US recommendation
Novo Nordisk's GLP-1/insulin combination, Xultophy, Moves One Step Closer to Approval in Europe
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Novo posts strong performance, but US pricing pressure grows | pharmaphorum
Xultophy® 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight vs basal-bolus therapy
Peter Falck Christens, Manager Biostatistics IdegLira, (Novo Nordisk) — Ministry of Music
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients
US approval for Novo Nordisk's Xultophy/IDegLira as diabetes battle hots up
Dosificación, Titulación y Aplicación de iDegLira - Novo Nordisk
Liraglutide Insulin Degludec Ideglira Xultophy (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Positive Phase 3b study resutls for Xultophy announced
ADA 2014: New data on Novo Nordisk's IDegLira and Victoza
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes
In a showdown with Sanofi, FDA questions Novo's PhIII data for IDegLira | Fierce Biotech
Switching to a fixed-ratio combination of insulin degludec/liraglutide ( IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the
REMIT-iDegLira - Research Studies - PHRI - Population Health Research Institute of Canada
Novo Nordisk Annual Report 6-K Prepared by Imprima
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy – topic of research paper in Clinical medicine. Download scholarly article PDF and read for
Insulin Degludec Insulin Aspart (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Overview of studies design evaluating the efficacy of iDegLira and... | Download Scientific Diagram
